COVID-19 vaccine speed unlikely to become norm
The speed of the COVID-19 vaccine development is unlikely to be repeated in normal drug testing, according to American Century fund manager, Michael Li, due to ongoing tension between drug companies and the regulator.
Li, who managed the Zurich Investments ACI Healthcare Impact fund, said his fund was focused on finding international companies which were focused on innovation and were making a social impact. This included biotechnology, healthcare providers and pharmaceuticals.
Particular areas which benefited during the pandemic were tele-health providers, diagnostic testing and medical device manufacturers.
He said it was “impressive” how fast the COVID-19 vaccine was developed by multiple companies such as Pfizer, Moderna and AstraZeneca, which prevented sales being dominated by one company. However, he did not think this experience would be common going forward when it came to drug testing trials.
He was also watching for how effective the vaccine would be and whether new variants would need to be developed to handle new strains of the virus.
“The pandemic was a special situation and received lots of funding though. In this case, there had been lots of knowledge accumulated of other coronaviruses and that could be quickly used to establish how a vaccine could be developed,” he said.
“In the future, a lot will depend on whether the regulator is willing to co-operate with drug companies on the approval process. In this case, there was a joint agreement between the industry and government agencies to co-operate quickly but typically, drug testing is very strict with large pools of patients and it will likely revert back to that.”
He said government policy was very important in the healthcare space and that he expected better performance from the sector now that uncertainty around the US presidential election was over.
“Government policy is very important and is very critical for all types of healthcare providers. The government has a lot of power so it is always something we have to watch.
“There was relative underperformance last year due to the political uncertainty in the US, we think there is more clarity now and Obamacare is less likely to be reversed. Overall, we feel optimistic on the sector.”
AUTHOR
Laura Dew
Recommended for you
Perpetual has released its Q2 fund flows showing a fall back into outflows after a positive Q1, as well as an update on its planned deal with KKR.
Magellan has announced a raft of executive changes including the departure of head of investments Gerald Stack after 18 years and a second appointment from Maple-Brown Abbott.
Morningstar research of seven active Australian asset managers has found they are expected to see client redemptions averaging 3.1 per cent of their FUM per annum through to FY29, with two forecast to lose more than 10 per cent.
Franklin Templeton is to get rid of its Martin Currie branding and fold them into the wider group under ClearBridge Investments and Franklin Equity Group.
